KB-1272

REGN5668-MUC16-hIgG4m01

12269

Home » Antibodies » REGN5668-MUC16-hIgG4m01

Background of REGN5668-MUC16-hIgG4m01

CA125 is a repeating peptide epitope of the mucin MUC16, which promotes cancer cell proliferation and inhibits anti-cancer immune responses. CA125 has been extensively studied as a biomarker in three distinct clinical scenarios: (1) as a screening test for early detection of ovarian cancer, (2) to differentiate between benign and malignant diseases in pre- and post-menopausal women with pelvic masses, and (3) to track the response to therapy in women with ovarian cancer.

Specifications

Catalog Number	KB-1272
Antibody Name	REGN5668-MUC16-hIgG4m01
Isotype	Human IgG1,kappa
FC Muations	S228P
Target	MUC16
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Véniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, Wu B, Falsey JR, Hager T, Thomas VA, Ambhaikar M, Sharpsten L, Zhu Y, Kurra V, Jeswani R, Oberoi RK, Parnes JR, Honarpour N, Neutel J, Strande JL. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6(2):290-303.
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus-NCT05669599